1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells

D J Mangelsdorf, H P Koeffler, C A Donaldson, J W Pike, M R Haussler, D J Mangelsdorf, H P Koeffler, C A Donaldson, J W Pike, M R Haussler

Abstract

The human-derived promyelocytic leukemia cell line, HL-60, is known to differentiate into mature myeloid cells in the presence of 1,25-dihydroxyvitamin D3 (1,25[OH]2D3). We investigated differentiation by monitoring 1,25(OH)2D3-exposed HL-60 cells for phagocytic activity, ability to reduce nitroblue tetrazolium, binding of the chemotaxin N-formyl-methionyl-leucyl-[3H]phenylalanine, development of nonspecific acid esterase activity, and morphological maturation of Wright-Giemsa-stained cells. 1,25(OH)2D3 concentrations as low as 10(-10) M caused significant development of phagocytosis, nitroblue tetrazolium reduction, and the emergence of differentiated myeloid cells that had morphological characteristics of both metamyelocytes and monocytes. These cells were conclusively identified as monocytes/macrophages based upon their adherence to the plastic flasks and their content of the macrophage-characteristic nonspecific acid esterase enzyme. The estimated ED50 for 1,25(OH)2D3-induced differentiation based upon nitroblue tetrazolium reduction and N-formyl-methionyl-leucyl-[3H]phenylalanine binding was 5.7 X 10(-9) M. HL-60 cells exhibited a complex growth response with various levels of 1,25(OH)2D3: less than or equal to 10(-10) M had no detectable effect, 10(-9) M stimulated growth, and greater than or equal to 10(-8) M sharply inhibited proliferation. We also detected and quantitated the specific receptor for 1,25(OH)2D3 in HL-60 and HL-60 Blast, a sub-clone resistant to the growth and differentiation effects of 1,25(OH)2D3. The receptor in both lines was characterized as a DNA-binding protein that migrated at 3.3S on high-salt sucrose gradients. Unequivocal identification was provided by selective dissociation of the 1,25(OH)2D3-receptor complex with the mercurial reagent, p-chloromercuribenzenesulfonic acid, and by a shift in its sedimentation position upon complexing with anti-receptor monoclonal antibody. On the basis of labeling of whole cells with 1,25(OH)2[3H]D3 in culture, we found that HL-60 contains approximately 4,000 1,25(OH)2D3 receptor molecules per cell, while the nonresponsive HL-60 Blast is endowed with approximately 8% of that number. The concentration of 1,25(OH)2D3 (5 X 10(-9) M) in complete culture medium, which facilitates the saturation of receptors in HL-60 cells, is virtually identical to the ED50 for the sterol's induction of differentiation. This correspondence, plus the resistance of the relatively receptor-poor HL-60 Blast, indicates that 1,25(OH)2D3-induced differentiation of HL-60 cells to monocytes/macrophages is occurring via receptor-mediated events.

References

    1. J Immunol. 1977 Jan;118(1):187-92
    1. J Biol Chem. 1983 Jul 25;258(14):8554-60
    1. Proc Natl Acad Sci U S A. 1977 Mar;74(3):1204-8
    1. Science. 1977 Sep 9;197(4308):1086-8
    1. N Engl J Med. 1977 Nov 10;297(19):1041-50
    1. J Immunol Methods. 1977;18(3-4):377-9
    1. Nature. 1977 Nov 24;270(5635):347-9
    1. Proc Natl Acad Sci U S A. 1978 May;75(5):2458-62
    1. Proc Natl Acad Sci U S A. 1979 Oct;76(10):5158-62
    1. Science. 1979 Dec 7;206(4423):1188-90
    1. Biochem Biophys Res Commun. 1979 Oct 12;90(3):1057-63
    1. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5485-9
    1. Infect Immun. 1979 Dec;26(3):996-9
    1. Life Sci. 1980 Feb 4;26(5):407-14
    1. Methods Enzymol. 1980;67:529-42
    1. J Biol Chem. 1980 May 25;255(10):4414-7
    1. Biochem Biophys Res Commun. 1980 Mar 13;93(1):9-15
    1. Proc Natl Acad Sci U S A. 1980 May;77(5):2936-40
    1. J Biol Chem. 1980 Sep 10;255(17):8035-7
    1. Biochem Biophys Res Commun. 1980 Jul 31;95(2):507-12
    1. Cancer Res. 1981 Mar;41(3):919-26
    1. Endocrinology. 1981 Mar;108(3):1083-6
    1. Leuk Res. 1981;5(4-5):429-30
    1. Biochem Biophys Res Commun. 1981 Aug 31;101(4):1131-8
    1. Am J Clin Pathol. 1971 Mar;55(3):283-90
    1. Biochemistry. 1973 Jun 19;12(13):2412-6
    1. J Biol Chem. 1974 Feb 25;249(4):1251-7
    1. J Biol Chem. 1974 Feb 25;249(4):1258-62
    1. Lancet. 1974 Nov 23;2(7891):1248-52
    1. Blood. 1976 Aug;48(2):309-13
    1. J Histochem Cytochem. 1976 Sep;24(9):979-83
    1. Biochem Biophys Res Commun. 1981 Oct 15;102(3):937-43
    1. Calcif Tissue Int. 1981;33(6):673-6
    1. J Clin Invest. 1982 Feb;69(2):277-83
    1. Proc Soc Exp Biol Med. 1982 Apr;169(4):421-6
    1. Ann N Y Acad Sci. 1981;372:502-17
    1. Proc Natl Acad Sci U S A. 1982 May;79(9):2865-9
    1. Biochem J. 1982 Jun 15;204(3):713-9
    1. Biochem Biophys Res Commun. 1982 Sep 16;108(1):414-20
    1. Proc Natl Acad Sci U S A. 1982 Dec;79(24):7719-23
    1. Proc Natl Acad Sci U S A. 1983 Jan;80(1):201-4
    1. Eur J Biochem. 1976 Dec 11;71(2):399-409

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe